Dyslipidemia and Hyperglycemia in Psoriatic Inpatients
Keywords:Psoriasis, Inpatients, Metabolic Syndrome, Dyslipidemias, Hyperglicemia
Background: Psoriasis is a chronic cutaneous T-cell mediated disease, which has been associated with many comorbidities, especially with metabolic disorders such as dyslipidemia, diabetes mellitus, obesity, and metabolic syndrome, many of which are themselves risk factors for other diseases. The goal of this study was to evaluate the presence of dyslipidemia and hyperglycemia in patients with psoriasis.
Methods: We compared 48 inpatients with plaque psoriasis aged 29-79, hospitalized between March 2018 and February 2019, to 48 age- and gender-matched controls. We evaluated dyslipidemia and hyperglycemia using enzymatic methods as part of a standard blood test, or medication history indicative of ongoing treatment of dyslipidemia and/or hyperglycemia. Hypertension was evaluated by registering blood pressure greater than 140/90 mmHg or ongoing antihypertensive treatment. Smoking habits were also noted.
Results: There were statistically significant differences between psoriasis patients and controls for elevated total cholesterol (p=0,028), elevated LDL (p=0,015), hypertriglyceridemia (p=0,006), and hyperglycemia (p=0,021). The two groups had statistically insignificant differences for lowered HDL (p=0,084), hypertension (p=1), and smoking (p=0,836).
Conclusion: Hypertriglyceridemia, hyperglycemia, and elevated LDL cholesterol were more prevalent in the group containing psoriatic patients compared to the control group. This indicates that further investigation of metabolic abnormalities should be conducted in psoriatic patients which could greatly benefit from early treatment of the aforementioned underlying conditions.
Christophers E. Psoriasis--epidemiology and clinical spectrum. Clin Exp Dermatol. 2001 Jun;26(4):314-20.
Boehncke W-H, Schön MP. Psoriasis. Lancet. 2015 Sep 5;386(9997):983-94.
Feingold KR, Grunfeld C. The Effect of Inflammation and Infection on Lipids and Lipoproteins: MDText.com, Inc., South Dartmouth (MA); 2000.
Armstrong AW, Harskamp CT, Armstrong EJ. Psoriasis and metabolic syndrome: A systematic review and meta-analysis of observational studies. J Am Acad Dermatol. 2013 Apr;68(4):654-662
Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest. 2006 Jul;116(7):1793-801.
Reynoso-von Drateln C, Martínez-Abundis E, Balcázar-Muñoz BR, Bustos-Saldaña R, González-Ortiz M. Lipid profile, insulin secretion, and insulin sensitivity in psoriasis. J Am Acad Dermatol. 2003 Jun;48(6):882-5.
Gisondi P, Fostini AC, Fossà I, Girolomoni G, Targher G. Psoriasis and the metabolic syndrome. Clin Dermatol. 2018 Jan - Feb;36(1):21-28.
Asha K, Singal A, Sharma SB, Arora VK, Aggarwal A. Dyslipidaemia & oxidative stress in patients of psoriasis: Emerging cardiovascular risk factors. Indian J Med Res. 2017 Dec;146(6):708-713
Nisa N, Qazi M. Prevalence of metabolic syndrome in patients with psoriasis. Indian J Dermatol Venereol Leprol. 2010 Nov-Dec;76(6):662-5.
Langan SM, Seminara NM, Shin DB, Troxel AB, Kimmel SE, Mehta NN, et al. Prevalence of Metabolic Syndrome in Patients with Psoriasis: A Population-Based Study in the United Kingdom. J Invest Dermatol. 2012 Mar;132(3 Pt 1):556-62.
Seçkin D, Tokgözoğlu L, Akkaya S. Are lipoprotein profile and lipoprotein (a) levels altered in men with psoriasis? J Am Acad Dermatol. 1994 Sep;31(3 Pt 1):445-9.
Piskin S, Gurkok F, Ekuklu G, Senol M. Serum Lipid Levels in Psoriasis. Yonsei Med J. 2003 Feb;44(1):24-6.
Solak Tekin N, Tekin IO, Barut F, Yilmaz Sipahi E. Accumulation of Oxidized Low-Density Lipoprotein in Psoriatic Skin and Changes of Plasma Lipid Levels in Psoriatic Patients. Mediators Inflamm. 2007;2007:78454.
Damevska K, Neloska L, Gocev G, Mihova M. Metabolic syndrome in untreated patients with psoriasis: case-control study. J Dtsch Dermatol Ges. 2013 Dec;11(12):1169-75.
Miao C, Li J, Li Y, Zhang X. Obesity and dyslipidemia in patients with psoriasis: A case-control study. Medicine (Baltimore). 2019 Aug;98(31):e16323.
Rocha-Pereira P, Santos-Silva A, Rebelo I, Figueiredo A, Quintanilha A, Teixeira F. Dislipidemia and oxidative stress in mild and in severe psoriasis as a risk for cardiovascular disease. Clin Chim Acta. 2001 Jan;303(1-2):33-9.
Itani S, Arabi A, Harb D, Hamzeh D, Kibbi A-G. High prevalence of metabolic syndrome in patients with psoriasis in Lebanon: a prospective study. Int J Dermatol. 2016 Apr;55(4):390-5.
Seishima M, Seishima M, Mori S, Noma A. Serum lipid and apolipoprotein levels in patients with psoriasis. Br J Dermatol. 1994 Jun;130(6):738-42.
Al-Mutairi N, Al-Farag S, Al-Mutairi A, Al-Shiltawy M. Comorbidities associated with psoriasis: An experience from the Middle East. J Dermatol. 2010 Feb;37(2):146-55.
Shiba M, Kato T, Izumi T, Miyamoto S, Nakane E, Haruna T, et al. Risk of myocardial infarction in patients with psoriasis: A cross-sectional patient-population study in a Japanese hospital. J Cardiol. 2019 Apr;73(4):276-279.
World Health Organization. Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia: report of a WHO/IDF consultation. 2006.
Gisondi P, Tessari G, Conti A, Piaserico S, Schianchi S, Peserico A, et al. Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case–control study. Br J Dermatol. 2007 Jul;157(1):68-73
How to Cite
Authors who publish with this journal agree to the following terms:
- The Author retains copyright in the Work, where the term “Work” shall include all digital objects that may result in subsequent electronic publication or distribution.
- Upon acceptance of the Work, the author shall grant to the Publisher the right of first publication of the Work.
- The Author shall grant to the Publisher and its agents the nonexclusive perpetual right and license to publish, archive, and make accessible the Work in whole or in part in all forms of media now or hereafter known under a Creative Commons Attribution 4.0 International License or its equivalent, which, for the avoidance of doubt, allows others to copy, distribute, and transmit the Work under the following conditions:
- Attribution—other users must attribute the Work in the manner specified by the author as indicated on the journal Web site; with the understanding that the above condition can be waived with permission from the Author and that where the Work or any of its elements is in the public domain under applicable law, that status is in no way affected by the license.
- The Author is able to enter into separate, additional contractual arrangements for the nonexclusive distribution of the journal's published version of the Work (e.g., post it to an institutional repository or publish it in a book), as long as there is provided in the document an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post online a prepublication manuscript (but not the Publisher’s final formatted PDF version of the Work) in institutional repositories or on their Websites prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work. Any such posting made before acceptance and publication of the Work shall be updated upon publication to include a reference to the Publisher-assigned DOI (Digital Object Identifier) and a link to the online abstract for the final published Work in the Journal.
- Upon Publisher’s request, the Author agrees to furnish promptly to Publisher, at the Author’s own expense, written evidence of the permissions, licenses, and consents for use of third-party material included within the Work, except as determined by Publisher to be covered by the principles of Fair Use.
- The Author represents and warrants that:
- the Work is the Author’s original work;
- the Author has not transferred, and will not transfer, exclusive rights in the Work to any third party;
- the Work is not pending review or under consideration by another publisher;
- the Work has not previously been published;
- the Work contains no misrepresentation or infringement of the Work or property of other authors or third parties; and
- the Work contains no libel, invasion of privacy, or other unlawful matter.
- The Author agrees to indemnify and hold Publisher harmless from the Author’s breach of the representations and warranties contained in Paragraph 6 above, as well as any claim or proceeding relating to Publisher’s use and publication of any content contained in the Work, including third-party content.
Enforcement of copyright
The IJMS takes the protection of copyright very seriously.
If the IJMS discovers that you have used its copyright materials in contravention of the license above, the IJMS may bring legal proceedings against you seeking reparation and an injunction to stop you using those materials. You could also be ordered to pay legal costs.
If you become aware of any use of the IJMS' copyright materials that contravenes or may contravene the license above, please report this by email to email@example.com
If you become aware of any material on the website that you believe infringes your or any other person's copyright, please report this by email to firstname.lastname@example.org